Treatment of cancer cells with these small inhibitors reduced phosphorylation of AKT, a target of NGAL activity [106], and decreased proliferation of ectopically NGAL overexpressing breast cancer cells [107]. This evidence concerns the gene LCN2 and breast cancer.